Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team

What are you looking for?

  • Conference Roundup
  • Contact Lenses
  • Diagnostics
  • Glaucoma
  • Myopia
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Retina
  • Spotlight Series
Navigating Presbyopia Conversations with Patients in Practice
Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team
Home > Full-spectrum lamp improves short-term symptoms of VDT-related dry eye
  • Ocular Surface Disease

Full-spectrum lamp improves short-term symptoms of VDT-related dry eye

Optometry 360

Key Takeaways

  1. OSDI scores improved significantly in both groups at 1 month, with greater symptom improvement among patients using the full-spectrum lamp plus artificial tears.
  2. NIBUT also improved in both groups, but the intervention did not produce significant between-group differences in NIBUT or other objective ocular surface measures.

Adding a full-spectrum lamp to artificial tears improved subjective dry eye symptoms more in the short term in patients with visual display terminal (VDT)-related dry eye, but did not result in differences in objective ocular surface measures between groups, according to a study.

The prospective randomized study included 66 patients with newly diagnosed VDT-related dry eye and limited corneal staining. Participants were assigned to a full-spectrum screen-bar lamp plus artificial tears (n = 34) or artificial tears alone (n = 32).

Primary endpoints were changes in Ocular Surface Disease Index (OSDI) and non-invasive tear breakup time (NIBUT) from baseline to one month.

The modified intention-to-treat analysis included 65 participants.

At 1 month, both groups showed significant improvements in OSDI scores (both P < 0.001), with the intervention group experiencing a greater improvement (adjusted between-group difference, −7.33; P = 0.042).

In both groups, NIBUT increased (P ≤ 0.017) with no significant between-group difference (adjusted difference, 0.26; P = 0.726).

Changes in tear meniscus height, conjunctival hyperemia, tear-film lipid layer thickness, and partial blinking rate did not differ significantly between groups. No study-related adverse events were reported.

Reference

Zhang N, Qiu C, Huang W, et al. Full-spectrum LED screen-bar lighting as an adjunct to artificial tears in visual display terminal-related dry eye: a randomized study. Int Ophthalmol. 2026;46(1):427. doi: 10.1007/s10792-026-04290-6. PMID: 42893472.

Share

Related Content

  • Ocular Surface Disease

DEWS III updates classification of dry eye disease risk factors

  • Ocular Surface Disease

Check the labels: products containing vitamin A can carry a risk of ocular adverse effects and MGD

  • Conference Roundup

Cash-pay dry eye marketing often outpaces available evidence

  • Conference Roundup

Affects dry eye can have on patients’ quality of life and more highlights from Academy 2026

  • Ocular Surface Disease

Apraclonidine 0.125% maintains ocular redness reduction over 8 weeks

  • Ocular Surface Disease

Greater screen use linked to dry eye symptoms in children

Share

Advisory Board

Kaleb Abbott, OD, MS, FAAO

Clark Chang, OD

Jessica Haynes, OD, FAAO, FORS, Dipl ABO

Monica Kalia, OD

Cecelia Koetting, OD, FAAO, DipABO

Roya Attar, OD, MBA, DHA, FAAO

Hardeep Kataria, OD, FAAO

Marc R. Bloomenstein, OD, FAAO

Elise Kramer, OD

See All
Optometry 360

Optometry 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

© 2026 Optometry 360 is a trademark of International Healthcare Media, LLC. All rights Reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophthalmology360 Icon